Shanghai Fosun terminates deal granting Sellas worldwide rights, excluding China, to two preclinical compounds in development for diabetes and lung cancer

Shanghai Fosun Pharmaceutical Group Co. Ltd.

China / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Sellas Life Sciences Group

Switzerland / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated